Literature DB >> 29866891

Expanding treatment for hepatitis C in Canada.

James F Crismale1, Jawad Ahmad2.   

Abstract

Mesh：

Year:  2018        PMID： 29866891      PMCID： PMC5988517          DOI： 10.1503/cmaj.170931

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.

Authors:  Zobair Younossi; Deidre Blissett; Rob Blissett; Linda Henry; Youssef Younossi; Rachel Beckerman; Sharon Hunt
Journal:  Liver Int       Date:  2017-08-24       Impact factor: 5.828

2.  Recommendations on hepatitis C screening for adults.

Authors:  Roland Grad; Brett Thombs; Marcello Tonelli; Maria Bacchus; Richard Birtwhistle; Scott Klarenbach; Harminder Singh; Veronique Dorais; Nathalie Holmes; Wendy Martin; Rachel Rodin; Alejandra Jaramillo Garcia
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

3.  Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C.

Authors: 
Journal:  J Hepatol       Date:  2017-06-29       Impact factor: 25.083

4.  Cost-effectiveness of screening for hepatitis C in Canada.

Authors:  William W L Wong; Hong-Anh Tu; Jordan J Feld; Tom Wong; Murray Krahn
Journal:  CMAJ       Date:  2015-01-12       Impact factor: 8.262

5.  EASL Recommendations on Treatment of Hepatitis C 2016.

Authors: 
Journal:  J Hepatol       Date:  2016-09-22       Impact factor: 25.083

6.  The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.

Authors:  David B Rein; Bryce D Smith; John S Wittenborn; Sarah B Lesesne; Laura D Wagner; Douglas W Roblin; Nita Patel; John W Ward; Cindy M Weinbaum
Journal:  Ann Intern Med       Date:  2011-11-04       Impact factor: 25.391

Review 7.  Direct-acting antivirals for chronic hepatitis C.

Authors:  Janus C Jakobsen; Emil Eik Nielsen; Joshua Feinberg; Kiran Kumar Katakam; Kristina Fobian; Goran Hauser; Goran Poropat; Snezana Djurisic; Karl Heinz Weiss; Milica Bjelakovic; Goran Bjelakovic; Sarah Louise Klingenberg; Jian Ping Liu; Dimitrinka Nikolova; Ronald L Koretz; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-06-06

8.  Model-based projection of health and economic effects of screening for hepatitis C in Canada.

Authors:  William W L Wong; Aysegul Erman; Jordan J Feld; Murray Krahn
Journal:  CMAJ Open       Date:  2017-08-25

9.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 10.  Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.

Authors:  Bryony Simmons; Jawaad Saleem; Katherine Heath; Graham S Cooke; Andrew Hill
Journal:  Clin Infect Dis       Date:  2015-05-17       Impact factor: 9.079
View more
  1 in total

1.  Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study.

Authors:  Zoë von Aesch; Amy Craig-Neil; Hemant Shah; Tony Antoniou; Christopher Meaney; Andrew D Pinto
Journal:  CMAJ Open       Date:  2021-03-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.